Jeil Pharmaceutical Co Ltd (271980)

Currency in KRW
13,430
-110(-0.81%)
Closed·

271980 Financial Summary

Key Ratios

P/E Ratio38.39
Price/Book1.02
Debt / Equity41.48%
Return on Equity3.55%
Dividend Yield0.00%
EBITDA-7.25B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
214.00 / --
Revenue / Forecast
137.63B / --
EPS Revisions
Last 90 days

FAQ

What were Jeil Pharma's earnings for the latest quarter?

The Jeil Pharma EPS (TTM) is 354.28. Jeil Pharma reported sales of 137,628.25, net income of 3,120.06, and EPS of 214.00 for the latest quarter.

What was Jeil Pharma's net income for the latest quarter?

Jeil Pharma's net income for the latest quarter was 3,120.06.

How did Jeil Pharma's performance compare year-over-year in the latest quarter?

The company's revenue moved from 163,023.87 in the previous quarter to 137,628.25 in the latest quarter, and net income moved from 2,619.56 to 3,120.06 compared to the previous quarter.

What is Jeil Pharma's net profit margin on a TTM basis?

Jeil Pharma's trailing twelve months (TTM) net profit margin is -4.25%.

How does Jeil Pharma's debt to equity ratio compare to industry standards?

Jeil Pharma's total debt-to-equity ratio is 41.48%.

What is Jeil Pharma's return on investment on a TTM basis?

Jeil Pharma's trailing twelve months (TTM) return on investment (ROI) is 3.55%.

Did Jeil Pharma gain or lose cash last quarter?

In the latest quarter, Jeil Pharma's net change in cash was 2,642.59 million.

What were Jeil Pharma's total assets and liabilities in the latest quarter?

As of the latest quarter, Jeil Pharma reported total assets of 485,939.03 million and total liabilities of 242,571.50 million.

How has Jeil Pharma's total revenue grown this year?

Jeil Pharma's total revenue was 163,023.87 in the previous quarter and 137,628.25 in the latest quarter.

What is Jeil Pharma's gross margin on a TTM basis?

Jeil Pharma's trailing twelve months (TTM) gross margin is 29.51%.

What was Jeil Pharma's revenue per share for the latest quarter?

Jeil Pharma's revenue per share for the latest quarter was 15,010.67.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.